NCT03338881View on ClinicalTrials.gov

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 10, 2018

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions
Advanced Solid NeoplasmsLymphoma Neoplasms
Interventions
DRUG

[14C]-TAK-659

\[14C\]-TAK-659 solution.

DRUG

TAK-659

TAK-659 tablets.

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY

NCT03338881 - A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies | Biotech Hunter | Biotech Hunter